Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular...

Area of Science:

• Oncology
• Molecular Biology
• Genomics
• Next-Generation Sequencing (NGS)

Background:

• Identifying somatic molecular alterations in tumors is crucial for understanding tumor biology and heterogeneity.
• Molecular markers enable personalized treatment assignment, but optimal clinical methods are under development.
• Targeted gene panels are essential for efficient and comprehensive tumor molecular profiling.

Purpose of the Study:

• To validate a targeted amplification-based NGS panel (Oncomine Comprehensive Assay v1) for solid tumor molecular profiling.
• To assess the assay's performance using various sample types, including FFPE, cell lines, and fresh frozen specimens.
• To determine the reliability of the assay for detecting diverse molecular alterations in clinical settings.

Main Methods:

• Validation of the Oncomine Comprehensive Assay v1, covering 143 genes, on a personal genome machine sequencer.
• Utilized low input DNA (20 ng) and RNA (10 ng) for the assay.
• Tested performance on 27 FFPE specimens, 10 cell lines, 24 commercial reference materials, and 26 OCT-embedded fresh frozen (OEFF) specimens.

Main Results:

• The NGS panel demonstrated high specificity (>99%) and sensitivity (>99%) across tested sample types.
• Low false-positive and false-negative rates were observed for single-nucleotide variants, indels, copy number alterations, and gene fusions.
• The assay proved effective for molecular profiling of both fixed and fresh frozen solid tumor samples, including core needle biopsies.

Conclusions:

• The validated targeted NGS assay is a reliable method for comprehensive molecular profiling of solid tumors.
• This assay provides accurate detection of key molecular alterations essential for personalized cancer therapy.
• The method's effectiveness on diverse sample types supports its clinical utility in oncology.